People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Other Health Care, Healthtech, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spirox, Inc. | — | Other Health Care | Series C | $98.2M | $1.0B | 2015 |
| Summus Global, Inc. | — | Other Health Care | Series B | $59.3M | $35.1M | 2021 |
| XII Medical, Inc. | — | Healthtech | Series B | $45.1M | $146.0M | 2020 |
| Puzzle Medical Devices Inc. | — | Healthtech | Series B | $30.0M | $168.5M | 2025 |
| KKR FlowMod Aggregator LLC | — | Biotechnology | Series B | $15.7M | $85.3M | 2025 |
| Protaryx Medical Inc. | — | Healthtech | Series A | $8.1M | $183.1M | 2020 |
| Serpex Medical Inc. | — | Biotechnology | Seed | $4.6M | $40.3M | 2020 |
| Verix Health, Inc. | — | Biotechnology | Seed | $1.5M | $66.6M | 2019 |
| Atriomx, Inc. | — | Other | Pre-Seed | $1.0M | $18.0M | 2021 |
Aftab Kherani at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Aftab Kherani on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Duke Rohlen | 5 | 10 |
| Doug Koo | 4 | 8 |
| Tony Natale | 3 | 5 |
| Douglas Koo | 2 | 7 |
| Shane Kreidel | 2 | 2 |
| Sasha Schrode | 2 | 2 |
| Camille Samuels | 1 | 6 |
| Douglas Rohlen | 1 | 5 |
| Anthony J. Natale | 1 | 5 |
| STACY ENXING SENG | 1 | 5 |
| Benjamin Pless | 1 | 5 |
| Dennis Purcell | 1 | 5 |
| Samuel Lee | 1 | 4 |
| Anthony Natale | 1 | 4 |
| Maria Berkman | 1 | 3 |
| Josh Nickols | 1 | 3 |
| Akhil Saklecha | 1 | 3 |
| JOSEPH RICH | 1 | 2 |
| Scott Harrison | 1 | 2 |
| James Gammie | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.